Related Experiment Video
Updated: Mar 14, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
ADAM17 substrate release in proximal tubule drives kidney fibrosis
Eirini Kefaloyianni1, Muthu Lakshmi Muthu1, Jakob Kaeppler1
1Renal Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Abstract:
Kidney fibrosis following kidney injury is an unresolved health problem and causes significant morbidity and mortality worldwide. In a study into its molecular mechanism, we identified essential causative features. Acute or chronic kidney injury causes sustained elevation of a disintegrin and metalloprotease 17 (ADAM17); of its cleavage-activated proligand substrates, in particular of pro-TNFα and the EGFR ligand amphiregulin (pro-AREG); and of the substrates' receptors. As a consequence, EGFR is persistently activated and triggers the synthesis and release of proinflammatory and profibrotic factors, resulting in macrophage/neutrophil ingress and fibrosis. ADAM17 hypomorphic mice, specific ADAM17 inhibitor-treated WT mice, or mice with inducible KO of ADAM17 in proximal tubule (Slc34a1-Cre) were significantly protected against these effects. In vitro, in proximal tubule cells, we show that AREG has unique profibrotic actions that are potentiated by TNFα-induced AREG cleavage. In vivo, in acute kidney injury (AKI) and chronic kidney disease (CKD, fibrosis) patients, soluble AREG is indeed highly upregulated in human urine, and both ADAM17 and AREG expression show strong positive correlation with fibrosis markers in related kidney biopsies. Our results indicate that targeting of the ADAM17 pathway represents a therapeutic target for human kidney fibrosis.
Insights
Kidney fibrosis, a major health issue, is driven by the ADAM17 enzyme pathway. Inhibiting ADAM17 or its substrate amphiregulin (AREG) shows promise for treating kidney fibrosis.
Area of Science:
- Biochemistry
- Molecular Biology
- Nephrology
Background:
- Kidney fibrosis is a significant cause of morbidity and mortality globally.
- The precise molecular mechanisms underlying kidney fibrosis remain incompletely understood.
Purpose of the Study:
- To elucidate the molecular mechanisms driving kidney fibrosis.
- To investigate the role of a disintegrin and metalloprotease 17 (ADAM17) and its substrates in kidney fibrosis.
- To evaluate the therapeutic potential of targeting the ADAM17 pathway.
Main Methods:
- Utilized ADAM17 hypomorphic mice, ADAM17 inhibitor-treated mice, and inducible ADAM17 knockout mice.
- Conducted in vitro studies using proximal tubule cells.
- Analyzed human urine and kidney biopsy samples from patients with acute kidney injury (AKI) and chronic kidney disease (CKD).
Main Results:
- Sustained elevation of ADAM17, pro-tumor necrosis factor-alpha (pro-TNFα), and pro-amphiregulin (pro-AREG) were identified as key drivers of kidney injury-induced fibrosis.
- Persistent activation of the epidermal growth factor receptor (EGFR) by these factors promotes profibrotic signaling.
- Inhibition of ADAM17 or genetic ablation significantly protected against kidney fibrosis.
- Elevated soluble AREG in human urine and correlated expression of ADAM17 and AREG with fibrosis markers in kidney biopsies were observed.
Conclusions:
- The ADAM17 pathway, including its substrates AREG and TNFα, plays a critical role in the pathogenesis of kidney fibrosis.
- Targeting ADAM17 offers a potential therapeutic strategy for treating kidney fibrosis in humans.
Related Concept Videos
Drug Elimination by Renal Route: Tubular Secretion
Renal Drug Excretion: Tubular Secretion
Nephrons
Renal Tubule and Collecting Duct
Proximal Convoluted Tubule (PCT):
The PCT is the initial segment of the renal tubule, extending from the Bowman's capsule that encloses the glomerulus. Its convoluted structure and microvilli-lined cells increase the surface area for reabsorption. The PCT reabsorbs glucose, amino acids, sodium, and water from the filtrate, ensuring essential...
Acute Kidney Injury II: Pathophysiology

